Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma

Annals of Oncology

Volumn 18, Issue 10, 2007, Pages 1680-1684

  Macdonald, D A ^a   Ding, K ^a   Gospodarowicz, M K ^b   Wells, W A ^b   Pearcey, R G ^c   Connors, J M ^d   Winter, J N ^e   Horning, S J ^f   Djurfeldt, M S ^a   Shepherd, L E ^a   Meyer, R M ^a,g  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e NORTHWESTERN UNIVERSITY   (United States)

^f STANFORD UNIVERSITY   (United States)

^g QUEEN S UNIVERSITY   (Canada)

Author keywords

Chemotherapy; Hodgkin; Limited stage; Relapse

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION FIELD; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 34848826221     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm287     Document Type: Article

References (17)

1. Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005; 23: 6400-6408.
2. Canellos GP. Chemotherapy alone for early Hodgkin's lymphoma: An emerging option. J Clin Oncol 2005; 23: 4574-4576.
3. Meyer RM, Gospodarowicz MK, Connors JM et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 4634-4642.
4. Meyer RM, Ambinder RF, Stroobants S. Hodgkin's lymphoma: Evolving concepts with implications for practice. hematology. Am Soc Hematol Educ Program 2004: 184-202.
5. Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 311: 1860-1861.
6. Lister TA. Crowther D Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636.
7. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma-diagnosis and treatment. Lancet Oncol 2004; 5: 19-26.
8. Yahalom J, Mauch P. The involved field is back: Issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002; 13 (Suppl 1): 79-83.
9. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
10. Fisher RA. The logic of inductive inference (with discussion). J R Statist Soc 1935; 98: 39-82.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958; 53: 457-481.
12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
13. Macdonald DA, Gospodarowicz MK, Wells WA et al. Relapse patterns and subsequent outcomes of patients treated on the NCIC CTG HD.6 (ECOG JHD06) randomized trial evaluating ABVD alone in patients with limited stage Hodgkin lymphoma (HL) [abstract]. Blood 2005; 106: 241a.
14. Hagenbeek A, Eghbali H, Fermé C et al. Three cycles of MOPP/ABV hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favorable supradiaphragmatic clinical stages HI Hodgkin's disease: Preliminary results of the EORTC-GELA H8-F randomized trial in 543 patients [abstract]. Blood 2000; 96: 575a.
15. Noordijk EM, Thomas J, Fermé C et al. First results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma [abstract]. J Clin Oncol 2005; 23: 561S.
16. Diehl V, Engert A, Mueller RP et al. HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group [abstract]. Journal of Clinical Oncology 2005; 23: 561S.
17. Rueda A, Olmos D, Viciana R et al. Treatment for relapse in stage I/II Hodgkin's lymphoma after initial single modality therapy. Clin Lymphoma Myeloma 2006; 6: 389-392.